Access the full text.
Sign up today, get unlimited access with DeepDyve Pro!
. JAMA Intern Med. 2014;174(10):1597-1604. Author Affiliations: Center for Health Equity Research and Promotion, 2. Arnold SV, Spertus JA, Lipska KJ, et al. Type of β- blocker use among patients ...
. JAMA Intern Med. 2014;174(10):1597-1604. Author Affiliations: Center for Health Equity Research and Promotion, 2. Arnold SV, Spertus JA, Lipska KJ, et al. Type of β- blocker use among patients ...
. JAMA Intern Med. 2014;174(10):1597-1604. Author Affiliations: Center for Health Equity Research and Promotion, 2. Arnold SV, Spertus JA, Lipska KJ, et al. Type of β- blocker use among patients ...
. JAMA Intern Med. 2014;174(10):1597-1604. Author Affiliations: Center for Health Equity Research and Promotion, 2. Arnold SV, Spertus JA, Lipska KJ, et al. Type of β- blocker use among patients ...
decliners ( ...
, angiotensin receptor blocker ; T2DM, type 2 diabetes mellitus. https://doi.org/10.1371/journal.pmed.1003707.g001 Exposure to study drugs We used a “pseudo-placebo” comparison group rather than an active ...
cohort. β- blockers are the most commonly prescribed CV medications among dialysis patients [14], but their cardioprotective role remains unclear. Observational data from the US Renal Data System identified ...
but without ESRD, was found to be 65%, whereas the prevalence among those with diabetic nephropathy was 87%. Although 5-year survival after a diagnosis of HF is generally very poor in patients on dialysis ( ...
Abstract Aims While patients with diabetes mellitus (DM) have more extensive coronary disease and worse survival after acute myocardial infarction (AMI) than patients without DM, data on whether ...
. Type of β- blocker use among patients with versus Eine Studie zeigt, dass vasodilatierende Mittel nur selten verordnet werden. without diabetes after myocardial infarction. Am Heart J. 2014;168:273–9 ...
Access the full text.
Sign up today, get unlimited access with DeepDyve Pro!